Clinical trials: Tumor Microenvironment
Multiple Myeloma
UARK 2003-33, Total Therapy III
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004).
- Trial name
- NCT00081939
- Testing
- Velcade, Thalidomide
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- University of Arkansas
Multiple Myeloma
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02112045
- Testing
- Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment…
- Trial name
- NCT04729959
- Testing
- Atezolizumab, Biospecimen Collection, Conventional Surgery
- Where
- 110 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
The main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with gemcitabine and abraxane.
- Trial name
- NCT03519308
- Testing
- Nivolumab, Nab-Paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Squamous Cell Carcinoma of the Head and Neck
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with…
- Trial name
- NCT04326257
- Testing
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dan Zandberg
Non-Small Cell Lung Cancer
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV…
- Trial name
- NCT02309892
- Testing
- L-DOS47
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Helix BioPharma Corporation
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Nutrition and Body Composition in Acute Lymphoblastic Leukemia
Many adolescents with acute lymphoblastic leukemia (ALL) have been found to have low bone density by the end of treatment. This can lead to long-term suffering in survivors due to poor bone health.
- Trial name
- NCT01317940
- Testing
- Vitamin D and Calcium Citrate
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT03795610
- Testing
- IPI-549
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Assuntina G. Sacco, MD
Adherence, Medication
Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention
Breast cancer patients commonly take medications to reduce the risk of recurrence, including aromatase inhibitors (AIs). AIs can cause significant side effects that reduce patient adherence.
- Trial name
- NCT03739983
- Testing
- Vaginal Renewal Program
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng
Soft-tissue Sarcomas
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).
- Trial name
- TARMIC (NCT02805725)
- Testing
- Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Bergonié
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer
Cabozantinib in Men With Castration-Resistant Prostate Cancer
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01703065
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Washington
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Background: Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous…
- Trial name
- NCT01030900
- Testing
- Campath, Rituximab, EPOCH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies the effects of acetylcysteine and topotecan hydrochloride on the tumor microenvironment, or cells that make up a tumor, compared to topotecan hydrochloride alone in patients with ovarian…
- Conditions
- Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02569957
- Testing
- Topotecan Hydrochloride, Acetylcysteine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University